Source: Medicines & Healthcare Products Regulatory Agency (GB) Revision Year: 2015 Publisher: Aventis Pharma Limited, One Onslow Street, Guildford, Surrey, GU1 4YS, UK or trading as: Sanofi-aventis or Sanofi, One Onslow Street, Guildford, Surrey, GU1 4YS, UK
Nalcrom 100mg Capsules.
| Pharmaceutical Form |
|---|
|
Capsule. Hard gelatin capsule with a clear cap and body, marked ‘SODIUM CROMOGLICATE 100 mg’ in black and containing a white powder. |
The active component per capsule is: Sodium Cromoglicate 100.0mg.
For a full list of excipients, see section 6.1.
| Active Ingredient | Description | |
|---|---|---|
| Cromoglicic acid |
Sodium cromoglicate (Cromoglicic acid) inhibits the activation of many of the cell types involved in the development and progression of asthma. Thus, sodium cromoglicate inhibits the release of inflammatory mediators including cytokines from mast cells and reduces the chemotactic activity of eosinophils and neutrophils. |
| List of Excipients |
|---|
|
Purified water Black ink containing: Water |
An aluminium can with aluminium screw cap containing 100 capsules or an HDPE bottle with screw cap containing 100 capsules.
Aventis Pharma Limited, One Onslow Street, Guildford, Surrey, GU1 4YS, UK
or trading as:
Sanofi-aventis or Sanofi, One Onslow Street, Guildford, Surrey, GU1 4YS, UK
PL 04425/0370
1st May 2005
| Drug | Countries | |
|---|---|---|
| NALCROM | Canada, Estonia, Netherlands, New Zealand, United Kingdom |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
